BHC Bausch Health Companies Inc.

-0.5  -2%
Previous Close 24.69
Open 24.58
Price To Book 3.1
Market Cap 8490914265
Shares 351,009,271
Volume 1,635,266
Short Ratio 2.16
Av. Daily Volume 4,310,165

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced May 7, 2018.
Plenvu (NER1006)
Bowel cleansing
Approval announced November 2, 2017.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
FDA approval announced February 25, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approval announced December 22, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
FDA Approval announced August 24, 2018.
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
Phase 3 trial to be initiated 2H 2018.
CRL issued June 18, 2018. Noted February 15, 2019 that the FDA has been unable to meet the PDUFA data of February 15, 2019 and expects a decision soon.
DUOBRII (halobetasol propionate and tazarotene)
Phase 3 trial initiated 2H 2017.
Approved February 15, 2017.
Approval announced March 2, 2018.
ULTRA - 7 days
Contact lens
ANDA filed. Approval expected 2019.
Allergic conjunctivitis
Phase 2 top-line data due 1H 2019.

Latest News

  1. Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?
  2. Bausch Health Shows Again It's Among Most Divisive Stocks
  3. Bullish Mizuho Says Bausch Health's Long-Term Guidance 'Within Reach'
  4. [$$] Synergy Pharma Bankruptcy Plan Cleared for Creditor Poll
  5. Did Changing Sentiment Drive Bausch Health Companies’s (NYSE:BHC) Share Price Down A Painful 83%?
  6. Is Bausch Health Companies (BHC) a Great Stock for Value Investors?
  7. Ortho Dermatologics Launches 2019 Aspire Higher Scholarship Program For Students With Dermatologic Conditions
  8. SILIQ™ (brodalumab) now covered by the RAMQ in Quebec
  9. Bausch Health Announces Closing Of Senior Secured Notes And Add-On Unsecured Notes, As Well As Redemption Of Existing Senior Notes
  10. Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
  11. Steven Tananbaum’s GoldenTree Asset Management’s Return, AUM, and Holdings
  12. See what the IHS Markit Score report has to say about Bausch Health Companies Inc.
  13. What Are Bausch Health’s Key Growth Drivers in 2019?
  14. Weekly CEO Buys Highlight
  15. BHC and Teva: How Tax Rate, Interest Expenses, and Capex Stack Up
  16. BHC and Teva: How Free Cash Flow and Net Debt Stack Up
  17. BHC or Teva: Who Is Controlling Expenses Better?
  18. BHC or TEVA: Who Is Expected to Report Faster EPS Growth?
  19. What Analysts Are Recommending for Bausch Health and Teva
  20. Bausch Health Companies Inc (BHC) CHAIRMAN & CEO Joseph C Papa Bought $710,100 of Shares